Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the potential of cinnamic acid for hair growth. It also mentions treatments like Minoxidil, finasteride, and RU58841.

The user experienced hair shedding and follicle shrinkage when using retinoic acid, despite trying different concentrations and frequencies. The hair loss persisted for six months but regrew after stopping the treatment.

The user is currently using 0.025% Pantostin but plans to switch to 0.1% Alfatradiol. They will also use high-dose Kx826, high-dose Minoxidil, and aggressive microneedling for hair regrowth.

Creating a carrier solution for topical hair loss treatments using ethanol, propylene glycol or glycerin, and instructions on creating topical finasteride. Different recipes are provided with varying ratios of alcohol to humectant.

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.

Finasteride increased the user's estrogen levels by 51%, causing concerns about gynecomastia and sleep issues. Despite potential side effects, the user prefers continuing finasteride to prevent hair loss, considering it essential for self-esteem.

A 27-year-old man shared his hormonal panel results after one year of taking finasteride 1mg/day for hair loss, showing his DHT levels nearly doubled. He reported stabilized hair loss with mild side effects that resolved, and he is considering a hair transplant but is concerned about the increased DHT levels and potential treatment options.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

JW0061 shows superior hair growth results compared to existing treatments, with significant increases in hair follicles. The Wnt/β-catenin pathway is crucial for hair growth, and JW0061 activates this pathway effectively.

A 20-year-old male is frustrated with his dermatologist for refusing to prescribe DHT blockers like finasteride or dutasteride, instead pushing for a hair transplant despite ongoing hair thinning. The user feels dismissed and unreasonably treated, and is advised by another user to find a better dermatologist and consider finasteride or dutasteride for effective treatment.

The conversation discusses using 0.1% Alfatradiol compounded by a pharmacy for hair loss treatment. It also mentions Minoxidil, finasteride, and RU58841 as other treatments.

Pyrilutamide, a drug in phase 3 trials in China, potentially becoming available in late 2023 or early 2024; Finasteride being used as a current treatment for hair loss; and the possibility of joining a group buy for black market versions of Pyrilutamide.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

Dutasteride is more effective than finasteride, has neuroprotective benefits, and may prevent acne. Despite initial concerns about metabolic effects, further research suggests it is safe for most users, especially if not hypogonadal.

The conversation discusses using topical liposomal finasteride for hair loss, with concerns about high DHT levels. The user's DHT level is above the normal range, which may affect hair health.

The conversation is about the availability of the research chemical GT20029 for hair loss treatment and when companies like Anageninc will have it. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

The user experienced significant hair loss after extended fasting, initially thought to be Telogen Effluvium, but later suspected male pattern baldness. They tried finasteride briefly but stopped due to concerns about side effects, and are unsure if the hair loss is due to Telogen Effluvium or another cause.

The conversation is about making topical finasteride using stemoxydine as a carrier. The user is considering buying Redken Cerafill Hair Re-Densifying Treatment (Stemoxydine) 90ml for this purpose.

The post discusses a user's successful hair regrowth using finasteride, dutasteride, topical minoxidil, and estrogen over nine months. The user, who is male-to-female (mtf), reports significant regrowth and no side effects beyond typical hormone replacement therapy effects.

The conversation discusses whether topical caffeine is effective for hair loss, with some users questioning its role due to its vasoconstrictive and vasodilative properties, while another suggests that temporary vasoconstriction might be beneficial by promoting angiogenesis. Specific treatments mentioned include caffeine shampoo, which one user believes is ineffective.

A 25-year-old MtF individual has been using oral finasteride, oral minoxidil, and MtF HRT to treat androgenic alopecia, resulting in significant hair regrowth. However, the regrown hairs remain thin and short, and they seek advice on how to make these hairs longer and thicker.

Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.

The user is hesitant to start Fin and Min due to their long-term commitment and is currently on a 2-month supplement course. Another user suggests that the supplements are ineffective and recommends using Fin and Min for androgenetic alopecia.

Hair loss treatments pyrilutamide and GT20029 discussed. Pyrilutamide approval in 2 years, GT20029 in 5-6+ years.

The user stopped using finasteride and RU58841 and is considering CB-03-01 for androgenic alopecia but is concerned about the cost and effectiveness, especially at a lower dose than in clinical trials. They are also using minoxidil, micro-needling, and nizoral shampoo but are unsure about the correct application method for CB-03-01.

Hair loss discussion includes Minoxidil, Finasteride, and RU58841 treatments. Users inquire about experiences with Pyrilutamide Kx group buys.

Azelaic acid is considered a strong DHT inhibitor with no reported sexual side effects, making it a potential alternative for those who cannot use finasteride. It can be used with minoxidil, but may cause skin irritation.

Topical finasteride is currently more effective than pyrilutamide for hair loss. Combining treatments like topical finasteride and pyrilutamide may enhance results due to different mechanisms.

The user experienced significant hair regrowth over 8 months using finasteride, minoxidil, and a custom topical mix including progesterone, cortisone, and alpha 5 estradiol. They reported no side effects and noticed improvement around the third month.

Clascoterone is being discussed for hair loss, but its current acne formulation may not be suitable for scalp use due to potential skin irritation and lower dosage compared to Breezula. Users mention other treatments like finasteride, minoxidil, and pyrilutamide, with some expressing skepticism about clascoterone's effectiveness for hair loss.